CalciMedica stockholders back plan increase, reverse split, and warrant issuances at annual meeting

CalciMedica, Inc. held its 2026 Annual Meeting of Stockholders on August 19, 2026, according to an 8-K filed the same day. As of July 21, 2026, the record date for the meeting, 30,736,401 shares of common stock were outstanding and entitled to vote.¹

Stockholders approved an amendment to the company's 2023 Equity Incentive Plan. The amendment raises the number of shares authorized for issuance under the plan by 7,500,000 shares and changes how the annual automatic share reserve increase is calculated to include shares issuable upon conversion or exercise of convertible preferred stock and pre-funded warrants.¹ The board had already approved this amended plan, subject to stockholder approval, on July 20, 2026.¹

In director elections, stockholders elected Allan Shaw and Robert N. Wilson as Class III directors, each to serve a three-year term through the 2029 annual meeting.¹ Baker Tilly US, LLP's appointment as the company's auditor for fiscal year 2026 was ratified. Shareholders also gave advisory approval to executive pay as described in the proxy statement, and voted for annual say-on-pay votes going forward, with the board committing to hold such votes every year until the next required frequency vote no later than the 2032 Annual Meeting.¹

Stockholders approved a reverse stock split. The amendment allows a reverse split at a ratio between 1-for-2 and 1-for-10, with the exact ratio and timing left to the board's discretion, if effected at all.¹

Two Nasdaq-related equity issuance proposals tied to a June 23, 2026 securities purchase agreement also passed. This covers Series A and Series B Warrants each exercisable for up to 18,673,429 shares, plus related warrant-linked shares.¹ A separate proposal approved warrants for 1,680,565 shares each of Series A and Series B to certain directors and officers under the same agreement.¹